Advertisement
 
YOU ARE HERE: LAT HomeCollectionsBotox
IN THE NEWS

Botox

HEALTH
May 12, 2008 | Jill U. Adams, Special to The Times
Growing older has its perks -- heftier income, respect of one's peers -- and its drawbacks such as, for men, a steady enlargement of the prostate gland. Soon, men with this problem may have a broader set of therapeutic options. A 2003 study already has revolutionized the standard of care men get for this common condition.
Advertisement
BUSINESS
May 8, 2008 | From Times Wire Services
Allergan Inc.'s net income more than doubled in the first quarter as sales accelerated outside the U.S. for the wrinkle remover Botox. Demand cooled in the U.S., and the company blamed the economy. Net income increased to $111.4 million, or 36 cents a share, from $43.8 million, or 14 cents, a year earlier, the company said. Revenue grew 23% to $1.08 billion, bolstered by converting overseas sales in other currencies to the dollar. Irvine-based Allergan sells cosmetic and medical products including breast implants, surgical devices to remedy obesity and a treatment for overactive bladders.
ENTERTAINMENT
April 13, 2008 | Mary McNamara, Times Television Critic
I know we're all supposed to be watching this season of "Dancing With the Stars" to see whether professional athletics or Broadway provides a better foundation for dance. But I'm pretty sure most of us are far too preoccupied with figuring out whether Priscilla Presley has had the first successful head transplant and why there wasn't a "Frontline" or at least an E! special about it.
AUTOS
March 26, 2008 | DAN NEIL
I would like to give my Nissan Murano test vehicle an Advil, or Tylenol, or perhaps I should Simoniz its hood with that HeadOn stuff that you apply directly to the forehead. This thing looks like it's suffering from the world's worst migraine. To signal, I suppose, the model-year face-lift, Nissan designers gave the 2009 Murano a tensed chrome brow, a fierce furrowing that is, actually, quite a bit more aggressive than anything else in the Nissan garage.
BUSINESS
March 5, 2008 | Lisa Girion, Times Staff Writer
The U.S. Department of Justice is looking at Allergan Inc.'s promotion of its blockbuster wrinkle drug Botox for medical uses, but investors didn't seem too worried about the news Tuesday. Allergan shares closed at $57.38, down $1.28 or 2.2% on word that the Irvine company received a subpoena from the U.S. Attorney's Office for the Northern District of Georgia demanding documents regarding its promotional and educational practices involving the use of the botulinum toxin-based drug for medical problems.
BUSINESS
February 9, 2008 | Lisa Girion, Times Staff Writer
Concerns about the widely used anti-wrinkle treatment Botox and a similar drug arose Friday as federal regulators said they were reviewing reports of at least one death and other serious reactions among some patients. Food and Drug Administration officials said they were not aware of any deaths among cosmetic users of Botox, the trade name for the blockbuster wrinkle buster made by Irvine's Allergan Inc.
BUSINESS
February 9, 2008 | By Lisa Girion, Los Angeles Times Staff Writer
Concerns about the widely used anti-wrinkle treatment Botox and a similar drug arose Friday as federal regulators said they were reviewing reports of at least one death and other serious reactions among some patients. Food and Drug Administration officials said they were not aware of any deaths among cosmetic users of Botox, the trade name for the blockbuster wrinkle buster made by Irvine's Allergan Inc. The FDA said it had reports of at least one death among patients who received a botulinum-based drug and what one official described as a "a relative handful" of serious side effects in which the toxin spread beyond the injection site.
IMAGE
February 3, 2008 | Monica Corcoran, Times Staff Writer
Last week, Reuters reported that a consumer group, Public Citizen, is lobbying U.S. authorities to strengthen the health warning on Botox and its kin, Myobloc. They want to see a "black box" warning -- similar to the health caveat plastered on cigarettes -- adhered to containers of the substances. What is most surprising, however, is that the group studied 180 reports submitted to the FDA and noted that in the 16 deaths caused by Botox, four of those fatalities occurred in patients under 18.
BUSINESS
November 26, 2007 | Lisa Girion, Times Staff Writer
In his corner office, Mr. Botox looked his age. He hadn't had a shot of botulinum toxin in a while, and the furrow between his brows was back. "You would never know I'm really 75 years old," David E.I. Pyott said, trotting out a well-worn joke that he likes to make "because of who I am." He's the man who made a muscle-controlling poison the most fashionable weapon against aging. And he's really 54. When Allergan Inc. hired him as chief executive in 1998, it was generating annual revenue of $1.
Los Angeles Times Articles
|